

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 575)

AUDITED FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2025

CORPORATE STATEMENT

Regent Pacific is a Hong Kong-based biopharmaceutical and investment company. Our vision is to create a royalty pharma company by generating substantial royalties and milestone payments from “out licensing” the rights to our drugs to large pharma over time. In addition, our aim is being the leader in the journey of longevity through the provision of our cutting-edge AI-enabled ageing clocks through the provision of a B2B2C SaaS platform.

Our aims are to drive robust value enhancing growth through:

- The generation of royalties and milestones from existing and new “out licensing” agreements; and
- The commercialisation of our leading scientifically backed AI-enabled ageing clocks and preventative health solutions.

Our strategy is focussed on Greater China, the US, the UK and Europe because of its strong growth profile and because it is where the Group has long experience, deep knowledge and strong relationships.

CHAIRMAN'S STATEMENT

On behalf of the Board, we are pleased to present the audited final results of the Company for the year ended 31 December 2025. During 2025, the Company continued to strengthen its position as a commercial-stage biopharmaceutical company, delivering sustained progress in commercial execution, advancing our vision to generate royalties and milestone payments from “out licensing” the rights to our drugs to large pharma and being the leader in the journey of longevity through the provision of our cutting edge AI-driven ageing clocks.

The year was characterised by steady execution in our commercial operations, continued investment in innovation, and disciplined capital management. The Board remains focused on ensuring that the Company is well positioned to deliver long-term value for shareholders while advancing our vision and strategic plan to drive robust value enhancing growth.

Commercial Performance

The Company has two, 100% owned proprietary products:

- Fortacin™ (or Senstend™ in China), an approved treatment for premature ejaculation; and
- Deep Longevity, an AI digital health company, focussed on longevity, health and wellness through its AI-powered ageing clocks that predict biological and psychological age.

China and the broader Greater China region remain central to the Company's near-term strategy through the approval of Senstend™ by the NMPA in China. We continued to work closely with our commercial strategic partner, Wanbang Biopharmaceutical and the regulatory authorities in China, to support product approval. And while we hoped that Wanbang Biopharmaceutical would gain approval for Senstend™ in December 2025, they are hopeful that approval can be obtained by the end of June 2026.

The Company remains committed to aligning with evolving regulatory frameworks while ensuring that the highest standards of quality, safety, and compliance are maintained.

We remain excited about the future potential of Senstend™ where the drug has the potential to help an initial target market of approximately 9 million patients in China in its first year of launch, growing to over 170 million patients by its tenth year. We have a strong commercial partner in Wanbang Biopharmaceutical, who has the necessary sales and marketing expertise, established e-commerce platforms and an unrivalled national distribution network of hospitals, clinics and pharmacies to help ensure the commercial success of Senstend™ in China.

2025 was a foundational year for Deep Longevity as we expanded geographically, strengthened our commercial and technical capabilities, and advanced our product suite towards greater scalability and differentiation. We launched into new markets, enhanced our core biological age prediction platform, broadened language and regional support, and made meaningful progress toward next-generation AI-based ageing clocks, including Face Age and Biometric Age.

While the longevity industry continues to evolve and adoption remains uneven across segments, we believe Deep Longevity has strengthened its technological leadership, expanded its commercial pipeline, and positioned itself for accelerated growth in 2026, particularly in the US and emerging markets such as Thailand.

Our mission at Deep Longevity remains as one to revolutionise the journey of longevity by providing advanced, scientifically backed reliable ageing clocks and preventative health solutions. The market is massive, worth over US\$6 trillion, and our AI-enabled technology provides entry into this large and growing longevity and global wellness market.

Corporate Governance

The Board is committed to maintaining high standards of corporate governance in accordance with the CG Code. Strong governance practices are fundamental to maintaining investor confidence and ensuring the sustainable development of the Company.

Throughout the year, the Board and its committees continued to provide oversight of the Company's strategic direction, financial performance, risk management framework, and internal control systems. Particular focus was placed on regulatory compliance, product quality oversight, pharmacovigilance, and information disclosure obligations associated with being a Hong Kong-listed issuer.

The Board also regularly reviews governance practices to ensure alignment with international best practices and the expectations of institutional investors.

Outlook

Looking ahead, we believe the outlook remains positive, particularly in Asia and China where demand for innovative therapies continues to grow. Regulatory reform, increasing healthcare investment, and expanding patient access are expected to support long-term sector development.

For the Company, the key priorities in the coming years include expanding the commercial reach of our existing products by exploring strategic partnerships and licensing opportunities that will generate royalty and milestone income and enhance our capabilities and product portfolio.

At the same time, the Board remains mindful of the broader geopolitical tensions, macroeconomic, and industry dynamics, including evolving reimbursement environments, regulatory developments, and competitive pressures within the sector. The Company will continue to pursue growth with a disciplined and strategic approach.

Our Performance

During the year, the Group recorded a loss attributable to shareholders of the Company of approximately US\$4.71 million, which was mainly attributable to the Group's operating and R&D expenses of approximately US\$4.66 million.

On behalf of the Board, the Company would like to thank our management team, employees, partners, and stakeholders for their ongoing contributions. We would also like to extend our kind appreciation to our Shareholders for their continued trust and support.

Conclusion

In summary, 2025 has been a year of continued progress and the Board remains confident in the Company's strategy, governance framework, and long-term growth prospects.

We look forward to building on this momentum in the years ahead.

**CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER
COMPREHENSIVE INCOME**

For the year ended 31 December 2025

	Notes	2025 US\$'000	2024 US\$'000
Revenue	4	363	719
Other income	4	—*	85
Exchange losses, net	7	(15)	(68)
Fair value loss on FAFVPL	7	—*	—*
Loss on disposal of FAFVPL	7	—	(80)
		<u>348</u>	<u>656</u>
Expenses:			
Employee benefit expenses	7	(3,004)	(2,987)
Rental and office expenses		(132)	(132)
Information and technology expenses		(145)	(153)
Marketing costs		(22)	(14)
Professional and consulting fees		(367)	(551)
Research and development expenses		(783)	(938)
Other operating expenses		(207)	(218)
		<u>(4,312)</u>	<u>(4,337)</u>
Loss from operations		(4,312)	(4,337)
Impairment loss on right-of-use assets	7	(30)	—
Finance costs	5	(368)	(171)
		<u>(4,710)</u>	<u>(4,508)</u>
Loss before tax		(4,710)	(4,508)
Income tax credit	6	—	26
		<u>—</u>	<u>26</u>
Loss for the year	7	<u>(4,710)</u>	<u>(4,482)</u>

* Amount is less than US\$1,000

**CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER
COMPREHENSIVE INCOME (CONTINUED)**

For the year ended 31 December 2025

	Notes	2025 US\$'000	2024 US\$'000
Other comprehensive expense:			
Item that may be reclassified to profit or loss:			
Exchange differences on translating foreign operations		4	6
		<u>4</u>	<u>6</u>
Total comprehensive expense for the year		<u>(4,706)</u>	<u>(4,476)</u>
Loss per share	9	US cents	US cents
– Basic		<u>(1.80)</u>	<u>(1.96)</u>
– Diluted		<u>(1.80)</u>	<u>(1.96)</u>
		HK cents	HK cents
– Basic		<u>(14.05)</u>	<u>(15.31)</u>
– Diluted		<u>(14.05)</u>	<u>(15.31)</u>

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 31 December 2025

	Notes	2025 US\$'000	2024 US\$'000
ASSETS AND LIABILITIES			
Non-current assets			
Property, plant and equipment		15	8
Right-of-use assets		–	–
Intangible assets		–	–
Interest in an associate		1	1
Financial assets at fair value through other comprehensive income		–*	–*
Total non-current assets		<u>16</u>	<u>9</u>
Current assets			
Financial assets at fair value through profit or loss		21	21
Trade receivables	10	82	53
Prepayments, deposits and other receivables		285	369
Tax recoverable		–	26
Restricted bank balances		32	32
Cash and bank balances		135	100
Total current assets		<u>555</u>	<u>601</u>
Current liabilities			
Trade payables, contract liabilities, accruals and other payables	11	(3,273)	(3,173)
Bank borrowings		(4)	(8)
Shareholder's loans		(3,620)	(2,000)
Lease liabilities		(303)	(468)
Total current liabilities		<u>(7,200)</u>	<u>(5,649)</u>
Net current liabilities		<u>(6,645)</u>	<u>(5,048)</u>
Total assets less current liabilities		<u>(6,629)</u>	<u>(5,039)</u>

CONSOLIDATED STATEMENT OF FINANCIAL POSITION (CONTINUED)
As at 31 December 2025

	Notes	2025 US\$'000	2024 US\$'000
Non-current liabilities			
Bank borrowings		–	(3)
Shareholder's loans		–	(570)
Lease liabilities		(12)	(289)
		(12)	(862)
Total non-current liabilities		(12)	(862)
NET LIABILITIES		(6,641)	(5,901)
EQUITY			
Share capital		292	228
Reserves		(6,933)	(6,129)
		(6,641)	(5,901)
CAPITAL DEFICIENCY		(6,641)	(5,901)

* Amount is less than US\$1,000

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2025

1. General Information

The Company was incorporated in the Cayman Islands with limited liability. The address of its registered office is at P.O. Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands. The address of its principal place of business is 8th Floor, Henley Building, 5 Queen's Road Central, Hong Kong. The Company's shares are listed on the Main Board of the Stock Exchange and are also traded on the Open Market (Freiverkehr) of the Frankfurt Stock Exchange.

The Company is engaged in investment holding. The principal activities of the Company and its subsidiaries consist of investments in biopharma companies and other corporate investments.

In the opinion of the Directors, the Company's ultimate controlling party is Mr James Mellon, the chairman of the Company.

The consolidated financial statements are presented in US dollars, which is also the functional currency of the Company.

2. Application of new and amendments to HKFRS Accounting Standards

(a) Amendments to an HKFRS Accounting Standard that are mandatorily effective for the current year

The Group has applied amendments to HKAS 21, The effects of changes in foreign exchange rates – Lack of exchangeability issued by the HKICPA to these financial statements for the current period. The application of the amendments has had no material impact on these financial statements.

The Group has not applied any new standard or interpretation that is not yet effective for the current accounting period.

(b) New and amendments to HKFRS Accounting Standards in issue but not yet effective

The Group has not early applied the following new and amendments to HKFRS Accounting Standards that have been issued but are not yet effective:

	Effective for accounting periods beginning on or after
Amendments to HKFRS 9 and HKFRS 7 – Amendments to the Classification and Measurement of Financial Instruments	1 January 2026
Amendments to HKFRS 9 and HKFRS 7 – Contracts Referencing Nature-dependent Electricity	1 January 2026
Amendments to HKFRS Accounting Standards – Annual Improvements to HKFRS Accounting Standards Volume 11	1 January 2026
HKFRS 18 – Presentation and Disclosure in Financial Statements	1 January 2027
Amendments to HKFRS 10 and HKAS 28 – Sale or Contribution of Assets between an Investor and its Associate or Joint Venture	To be determined by the HKICPA

Except for HKFRS 18 mentioned below, the Directors anticipate that the application of all other amendments to HKFRS Accounting Standards will have no material impact on the consolidated financial statements in the foreseeable future.

HKFRS 18 Presentation and Disclosure in Financial Statements

HKFRS 18 Presentation and Disclosure in Financial Statements, which sets out requirements on presentation and disclosures in financial statements, will replace HKAS 1 Presentation of Financial Statements. This new HKFRS Accounting Standard, while carrying forward many of the requirements in HKAS 1, introduces new requirements to present specified categories and defined subtotals in the statement of profit or loss; provide disclosures on management-defined performance measures (MPMs) in the notes to the financial statements and improve aggregation and disaggregation of information to be disclosed in the financial statements. In addition, some HKAS 1 paragraphs have been moved to HKAS 8 Accounting Policies, Changes in Accounting Estimates and Errors (the title of which will be changed to Basis of Preparation of Financial Statements upon effective of HKFRS 18) and HKFRS 7 Financial Instruments: Disclosures – Gain or loss on derecognition. Minor amendments to HKAS 7 Statement of Cash Flows and HKAS 33 Earnings per Share are also made.

HKFRS 18, and amendments to other standards, will be effective for annual periods beginning on or after 1 January 2027, with early application permitted. HKFRS 18 requires retrospective application with specific transition provisions. The application of the new standard is expected to affect the presentation of the consolidated statement of profit or loss and other comprehensive income and disclosures in the future financial statements. The Group is in the process of assessing the detailed impact of HKFRS 18 on the Group's consolidated financial statements.

3. Basis of preparation of consolidated financial statements

The consolidated financial statements have been prepared in accordance with HKFRS Accounting Standards as issued by the HKICPA. For the purpose of preparation of the consolidated financial statements, information is considered material if such information is reasonably expected to influence decisions made by primary users. In addition, the consolidated financial statements include applicable disclosures required by the Rules Governing the Listing of Securities on the Stock Exchange and by the Hong Kong Companies Ordinance.

The consolidated financial statements have been prepared on the historical cost basis except for certain financial instruments that are measured at fair values at the end of each reporting period, as explained in the accounting policies set out below.

Historical cost is generally based on the fair value of the consideration given in exchange for goods and services.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or a liability, the Group takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date. Fair value for measurement and/or disclosure purposes in these consolidated financial statements is determined on such a basis, except for share-based payment transactions that are within the scope of HKFRS 2 *Share-based Payment*, leasing transactions that are accounted for in accordance with HKFRS 16 *Leases* (“**HKFRS 16**”), and measurements that have some similarities to fair value but are not fair value, such as net realisable value in HKAS 2 *Inventories* or value in use in HKAS 36 *Impairment of Assets*.

In addition, for financial reporting purposes, fair value measurements are categorised into Level 1, 2 or 3 based on the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows:

- Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;
- Level 2 inputs are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly; and
- Level 3 inputs are unobservable inputs for the asset or liability.

The Directors, have at the time of approving the consolidated financial statements, a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future. Thus, they continue to adopt the going concern basis of accounting in preparing the consolidated financial statements.

The Group incurred a loss of approximately US\$4,710,000 during the year ended 31 December 2025. As at 31 December 2025, the Group had net current liabilities and net liabilities of approximately US\$6,645,000 and US\$6,641,000 respectively.

These events and conditions indicate the existence of a material uncertainty which may cast significant doubt about the Group’s ability to continue as a going concern and to realise its assets and discharge its liabilities in the normal course of business.

Nevertheless, the Directors had adopted the going concern basis in the preparation of these consolidated financial statements of the Group, based on the expectation and measures including but not limited to the following:

- (a) on 26 March 2026, Galloway has granted a facility to the Company for an amount of up to US\$3,000,000. The facility is unsecured, interest bearing at 12% per annum and the principal together with any interest accrued shall be repaid on the date falling eighteen months from the date of the facility letter, unless extended by mutual consent;
- (b) also on 20 March 2026, Galloway has agreed to extend the repayment of the loans of US\$4,190,000 for the facility dated 20 March 2025 and agreed not to demand repayment of the loans on maturity date until the Company is in a position to repay; and
- (c) the Group anticipates approval by the NMPA in China on Senstend™ in 2026 and will also seek to implement operational plans to control costs and generate sufficient operating cash flows to meet its current and future obligations. These actions include cost control measures, and timely collection of outstanding receivables.

The Directors have estimated the Group's cash requirements by preparing a Group cashflow forecast for the 15 months ending 31 March 2027. The Directors are of the opinion that the Group has sufficient working capital for its present requirements, that is for 15 months ending 31 March 2027. Accordingly, the Directors are of the view that it is appropriate to adopt the going concern basis in preparing these consolidated financial statements.

Notwithstanding, material uncertainty exists as to whether the Group will be able to continue as a going concern would depend upon the following:

- (a) successful draw down of the facility from Galloway as and when needed;
- (b) successful commercialisation of Senstend™ in China; and
- (c) successful implementation of measures to effectively control costs and expenses and timely collection of receivables.

Should the Group fail to achieve the above-mentioned plans and measures, it might not be able to continue to operate as a going concern, and adjustments would have to be made to write down the carrying value of the Group's assets to their recoverable amounts, to provide for any further liabilities that might arise, and to reclassify non-current assets and non-current liabilities as current assets and current liabilities respectively. The effect of these adjustments has not been reflected in these consolidated financial statements.

4. Revenue, other income and segment information

Revenue of the Group consists of royalty income, a signature payment and income generated from the IP. An analysis of the Group's revenue and other income for the year is as follows:

	2025 US\$'000	2024 US\$'000
Royalty income	228	154
Signature payment	–	500
Income generated from the IP (Deep Longevity):		
– Subscription and support service	133	63
– Provision of biological age reports	2	2
	<u>363</u>	<u>719</u>
Revenue from contracts with customers		
	<u>363</u>	<u>719</u>
Other income		
– Bank interest income	–*	3
– Sundry income	–	82
	<u>–*</u>	<u>85</u>
	<u>363</u>	<u>804</u>

* Amount is less than US\$1,000

The Group identifies operating segments and prepares segment information based on the regular internal financial information reported to the CEO for his decision about resources allocation to the Group's business components and for his review of the performance of those components. The business components in the internal financial information reported to the CEO are determined following the Group's major product and service lines.

For management purpose, the Group's two product and service lines are identified as operating segments as follows:

Biopharma : Research, development, manufacturing, marketing and sale of pharmaceutical products and development of AI system for the field of biological ageing clocks

Corporate Investment : Investment in corporate entities, both listed and unlisted

These operating segments are monitored and strategic decisions are made on the basis of segment operating results. There were no sales between the reportable segments.

The measurement policies the Group uses for reporting segment results under HKFRS 8 are the same as those used in its financial statements prepared under HKFRS Accounting Standards, except that:

- finance costs; and
- impairment loss on right-of-use assets;

are not included in arriving at the operating results of the operating segment.

Segment assets include all assets except for interest in an associate and asset classified as held for sale.

Segment liabilities exclude lease liabilities and shareholder's loans.

Information regarding the Group's reportable segments is set out below:

For the year ended 31 December 2025

	Biopharma US\$'000	Corporate Investment US\$'000	Total US\$'000
Revenue from external customers	<u>363</u>	<u>–</u>	<u>363</u>
Segment loss	(805)	(3,507)	(4,312)
Impairment loss on right-of-use assets			(30)
Finance costs			<u>(368)</u>
Loss before tax			<u>(4,710)</u>

For the year ended 31 December 2025

	Biopharma US\$'000	Corporate Investment US\$'000	Total US\$'000
Items included in arriving at segment results:			
Depreciation of property, plant and equipment	(1)	(7)	(8)
Fair value loss on FAFVPL	—	—*	—*

As at 31 December 2025

	Biopharma US\$'000	Corporate Investment US\$'000	Total US\$'000
Segment assets	220	350	570
Interest in an associate			1
Consolidated total assets			<u>571</u>
Segment liabilities	143	3,134	3,277
Shareholder's loans			3,620
Lease liabilities			315
Consolidated total liabilities			<u>7,212</u>

* Amount is less than US\$1,000

For the year ended 31 December 2024

	Biopharma US\$'000	Corporate Investment US\$'000	Total US\$'000
Revenue from external customers	<u>719</u>	<u>–</u>	<u>719</u>
Segment loss	(649)	(3,688)	(4,337)
Finance costs			<u>(171)</u>
Loss before tax			<u>(4,508)</u>

For the year ended 31 December 2024

	Biopharma US\$'000	Corporate Investment US\$'000	Total US\$'000
Items included in arriving at segment results:			
Depreciation of property, plant and equipment	(2)	(6)	(8)
Fair value loss on FAFVPL	–	–*	–*
Loss on disposal of FAFVPL	<u>–</u>	<u>(80)</u>	<u>(80)</u>

As at 31 December 2024

	Biopharma US\$'000	Corporate Investment US\$'000	Total US\$'000
Segment assets	278	331	609
Interest in an associate			1
Consolidated total assets			<u>610</u>
Segment liabilities	208	2,976	3,184
Shareholder's loans			2,570
Lease liabilities			757
Consolidated total liabilities			<u>6,511</u>

The Group's revenues from external customers and its non-current assets (other than financial instruments and interest in an associate) are divided into the following geographical areas:

	Revenue from external customers		Non-current assets	
	2025 US\$'000	2024 US\$'000	2025 US\$'000	2024 US\$'000
Europe	267	165	—*	1
US	9	18	—	—
Asia Pacific	87	536	15	7
	<u>363</u>	<u>719</u>	<u>15</u>	<u>8</u>

* Amount is less than US\$1,000

The geographical location of revenue from external customers is based on the location of customers of the Group's Biopharma segment. The geographical location of the non-current assets is based on the physical location of the assets.

Disaggregation of revenue

Disaggregation of revenue from the Group's Biopharma segment and timing of revenue recognition are as follows:

	2025 US\$'000	2024 US\$'000
Timing of revenue recognition		
At a point in time		
Royalty income	228	154
Signature payment	–	500
Provision of biological age reports	2	2
	<u>230</u>	<u>656</u>
Over time		
Subscription and support service	133	63
	<u>363</u>	<u>719</u>

As at 31 December 2025, the aggregated amount of the transaction price allocated to the remaining performance obligations under the Group's existing contracts is approximately US\$26,000 (2024: approximately US\$52,000). This amount represents revenue expected to be recognised in the future from partially completed short-term subscription and support service contracts. The Group expects to recognise revenue in future when the service is provided, of which US\$26,000 (2024: US\$52,000) is expected to occur within one year.

Information about major customers

Revenue from customers of the Group's Biopharma segment contributing 10% or more of the Group's revenue is as follows:

	2025 US\$'000	2024 US\$'000
Customer A	228	154
Customer B	–	500

5. Finance costs

	2025 US\$'000	2024 US\$'000
Interest expense on shareholder's loans (note 26)	314	71
Interest expense on lease liabilities	54	100
	<u>368</u>	<u>171</u>

6. Income tax credit

The amount of income tax credit in the consolidated statement of profit or loss and other comprehensive income represents:

	2025 US\$'000	2024 US\$'000
Current tax		
– Credit for the year	<u>–</u>	<u>(26)</u>

No provision for Hong Kong Profits Tax has been made for the years ended 31 December 2025 and 2024 as the relevant group entities did not have assessable profits subject to Hong Kong Profits Tax for the year.

Pursuant to the relevant laws and regulations in the UK, subsidiaries of the Company in the UK are subject to UK corporate income tax ("CIT") at 25% (2024: 25%) during the year ended 31 December 2025. No provision for UK CIT has been made for the year ended 31 December 2025 as the relevant group entities did not have assessable income subject to UK CIT for the year (2024: no provision for UK CIT has been made as the relevant group entities have sufficient tax losses brought forward to set off against current year's assessable income).

Tax charge on profits assessable elsewhere have been calculated at the rates of tax prevailing in the countries in which the Group operates, based on existing legislation, interpretation and practices in respect thereof.

7. Loss for the year

	2025 US\$'000	2024 US\$'000
Loss for the year is arrived at after charging:		
Employee benefit expenses (including directors' remuneration)		
– salaries and benefits	2,937	2,840
– contributions to retirement benefit scheme	21	21
– equity-settled share-based payment expenses	46	126
	<u>3,004</u>	<u>2,987</u>
Auditors' remuneration		
– audit services	110	122
– non-audit services	19	19
Depreciation of property, plant and equipment	8	8
Impairment loss on right-of-use assets	30	–
Short-term leases expenses	15	15
Low-value assets lease expenses	3	3
Fair value loss on FAFVPL	–*	–*
Loss on disposal of FAFVPL	–	80
Exchange losses, net	15	68

* Amount is less than US\$1,000

8. Dividend

No dividend was paid or proposed during the year ended 31 December 2025, nor has any dividend been proposed since the end of the reporting period (2024: nil).

9. Loss per share

The calculation of basic loss per share is based on the loss attributable to the shareholders of the Company for the year and on the weighted average number of ordinary shares in issue during the year.

	2025 US\$'000	2024 US\$'000
Loss attributable to shareholders of the Company	<u>(4,710)</u>	<u>(4,482)</u>
Weighted average number of ordinary shares in issue	<u>261,429,471</u>	<u>228,413,933</u>
Basic loss per share (US cents)	<u>(1.80)</u>	<u>(1.96)</u>

The computation of diluted loss per share does not assume the exercise of the options because the exercise price of those Options was higher than the average market price for the Shares for the years ended 31 December 2025 and 2024. Accordingly, the diluted loss per share is the same as the basic loss per share.

10. Trade receivables

	2025 US\$'000	2024 US\$'000
Trade receivables	<u>82</u>	<u>53</u>

The Group applies credit policies appropriate to the particular business circumstances concerned generally requires outstanding amounts to be paid within 20 to 30 days (2024: 20 to 30 days) of invoice.

As at 31 December 2025 and 2024, the ageing analysis of trade receivables, based on the invoice dates, was as follows:

	2025 US\$'000	2024 US\$'000
Within 1 month	<u>82</u>	<u>53</u>

11. Trade payables, contract liabilities, accruals and other payables

	2025 US\$'000	2024 US\$'000
Trade payables	17	26
Contract liabilities – Deposits received in advance	26	52
Accruals and other payables	<u>3,230</u>	<u>3,095</u>
	<u><u>3,273</u></u>	<u><u>3,173</u></u>

As at 31 December 2025 and 2024, the ageing analysis of trade payables, based on the invoice dates, was as follows:

	2025 US\$'000	2024 US\$'000
Within 1 month or on demand	15	19
After 1 month but within 3 months	<u>2</u>	<u>7</u>
	<u><u>17</u></u>	<u><u>26</u></u>

MANAGEMENT'S DISCUSSION AND ANALYSIS OF THE GROUP'S PERFORMANCE

REVENUE AND PROFIT

The Group recorded a loss attributable to shareholders of the Company of approximately US\$4.71 million for the year ended 31 December 2025 (year ended 31 December 2024: approximately US\$4.48 million).

The main elements of the profit/(loss) are analysed as follows:

	Notes	Year ended 31 December		Increase/ (decrease) in absolute value
		2025 US\$ million	2024 US\$ million	value %
Revenue	(i)	0.36	0.72	(50.00)
Other income		–	0.08	(100.00)
Net exchange loss		(0.02)	(0.07)	(71.43)
Fair value gain/(loss) on financial instruments		–*	(0.08)	(100.00)
Impairment loss on right-of- use assets		(0.03)	–	NA
R&D expenditure	(ii)	(0.78)	(0.94)	(17.02)
G&A expenditure		(3.87)	(4.05)	(4.44)
Finance costs	(iii)	(0.37)	(0.17)	117.65
Income tax credit		–	0.03	(100.00)
Total loss attributable to shareholders of the Company		(4.71)	(4.48)	5.13

* Amount is less than US\$0.01 million

- (i) The Group's revenue of approximately US\$0.36 million for the year ended 31 December 2025 was lower than the revenue generated in the corresponding year in 2024 because the Group did not receive a signature payment in 2025.
- (ii) The Group's R&D expenditure of approximately US\$0.78 million for the year ended 31 December 2025 was slightly lower as compared to the corresponding year in 2024, where it was approximately US\$0.94 million. The reduction was mainly due to the decrease in the Group's personnel cost.
- (iii) The Group recorded an increase in its finance cost of approximately US\$0.37 million for the year ended 31 December 2025 as compared to approximately US\$0.17 million for the corresponding year in 2024, which was a result of an increase in the amount of weighted average outstanding shareholder's loan of approximately US\$3.06 million for the year ended 31 December 2025 as compared to approximately US\$0.88 million for the corresponding year in 2024.

Financial Position

Capital deficiency increased to approximately US\$6.64 million as at 31 December 2025 from approximately US\$5.90 million as at 31 December 2024. The increase was due to the loss attributable to shareholders of the Company of approximately US\$4.71 million for the year ended 31 December 2025, which was offset somewhat by the completion of the Loan Capitalisation of approximately US\$3.96 million on 25 June 2025.

The Group's assets mainly comprised: (i) cash and bank balances of approximately US\$135,000; (ii) property, plant and equipment and prepayment, deposits, and other receivables of approximately US\$300,000; (iii) restricted bank balances of US\$32,000; (iv) trade receivables of approximately US\$82,000; and (v) listed and unlisted investments of approximately US\$21,000.

The Group's liabilities mainly comprised: (i) trade payables, contract liabilities, accruals and other payables of approximately US\$3.27 million; (ii) long-term and short-term lease liabilities of approximately US\$315,000; (iii) long-term and short-term shareholder's loan of US\$3.62 million; and (iv) long-term and short-term bank borrowings of approximately US\$4,000.

Plethora's financial results

Plethora recorded an operating loss of approximately GBP 190,000 (or approximately US\$250,000) for the year ended 31 December 2025 (year ended 31 December 2024: profit of approximately GBP 96,000 (or approximately US\$123,000), excluding the amortisation cost of an intangible asset, Fortacin™, and the tax credit in respect of the deferred tax liability).

The operating results of Plethora for the year ended 31 December 2025, mainly included: (i) the royalty income of approximately GBP 173,000 (or approximately US\$228,000) (year ended 31 December 2024: the signature payment and royalty income of approximately GBP 509,000 (or approximately US\$655,000)) which being offset by: (ii) R&D costs related to the regulatory and Phase 3 studies in respect of the FDA approval process of Fortacin™ in the US of approximately GBP 157,000 (or approximately US\$207,000) (year ended 31 December 2024: approximately GBP 237,000 (or approximately US\$303,000)); and (iii) G&A expenses of approximately GBP 206,000 (or approximately US\$272,000) (year ended 31 December 2024: approximately GBP 260,000 (or approximately US\$336,000)).

As at 31 December 2025, Plethora had cash resources of approximately GBP 14,000 (or approximately US\$19,000) (31 December 2024: approximately GBP 25,000 (or approximately US\$32,000)), with ongoing financial support being provided by the Group.

Development Plan for Senstend™ in the PRC

During 2025, Wanbang Biopharmaceutical has received several rounds of questions from the NMPA on the clinical dossier, and in return it has addressed each of the questions in a timely manner. Wanbang Biopharmaceutical understands that there are no further questions on the clinical dossier.

In support of the NDA, Wanbang Biopharmaceutical has submitted for evaluation 900 commercial samples of Senstend™ that were manufactured by its manufacturing partner in Italy to the Centre of Drug Evaluation (CDE). Wanbang Biopharmaceutical has received several rounds of questions from the CDE, which have all been addressed in a timely manner through the responses received from the manufacturer and Plethora's regulatory consultant.

While Wanbang Biopharmaceutical was not able to obtain approval from the NMPA by the end of 2025, it remains optimistic that it will receive approval for market authorisation (an import license) by 30 June 2026, with first commercial launch projected to start in Q3 2026.

Upon approval by the NMPA, US\$5 million (before deduction of PRC withholding tax) shall be payable to the Group from Wanbang Biopharmaceutical. In addition, upon first commercial sale of Senstend™ in China, US\$2 million (before deduction of PRC withholding tax) shall be payable to the Group from Wanbang Biopharmaceutical. Thereafter the Group will receive ongoing royalties and milestone payments based on targets being met.

Development Plan for Fortacin™ in the US

In respect of the progress being made with Fortacin™ in the US, the Company has finalised discussions with the recommended contract research organisation (CRO) for undertaking the Phase 3 clinical studies. In addition, the Company is continuing discussions with a number of pharmaceutical companies for “out licensing” the rights to Fortacin™ for the US market for financing the Phase 3 clinical studies with a view to having these finalised during 2026, such that any upfront payments would be utilised to fund the Phase 3 studies in the US.

Commercialisation of Fortacin™ in Europe by Recordati

Recordati continues to receive uninterrupted supply of Fortacin™ and the leading markets are Italy, Germany, France and Portugal.

Commercialisation of Fortacin™ in other countries

The Group is in preliminary discussions with a large pharmaceutical company for “out licensing” Fortacin™ for certain key markets in the Middle East, South America, North America (excluding the US which is under discussions with US pharmaceutical companies) and certain other territories.

Kobayashi Pharmaceutical Co., Ltd., our commercial partner for the Japanese market, is progressing its regulatory pathway with a view to commencing clinical studies in 2026.

BUSINESS DEVELOPMENT OF DEEP LONGEVITY

Executive Summary

2025 was a foundational year for Deep Longevity as we expanded geographically, strengthened our commercial and technical capabilities, and advanced our product suite towards greater scalability and differentiation. We launched into new markets, enhanced our core biological age prediction platform, broadened language and regional support, and made meaningful progress toward next-generation AI-based ageing clocks, including Face Age and Biometric Age.

While the longevity industry continues to evolve and adoption remains uneven across segments, we believe Deep Longevity has strengthened its technological leadership, expanded its commercial pipeline, and positioned itself for accelerated growth in 2026, particularly in the US and emerging markets such as Thailand.

Commercial and Market Expansion

During 2025, we expanded our footprint into several key international markets, including China, India, and Thailand. These markets have demonstrated strong interest in longevity solutions, particularly among premium healthcare providers, diagnostics groups, telehealth platforms, and digital health ecosystems. We are currently engaged in discussions with multiple strategic partners, including diagnostic networks, E-commerce platforms, and telehealth companies, several of which represent large potential commercial opportunities.

To support expansion into the US, our most important growth market, we started hiring senior salespersons in the US since January 2026. The US represents our largest long-term commercial opportunity due to its scale, advanced longevity ecosystem, and concentration of premium healthcare providers. Building a dedicated commercial presence is a key strategic priority to accelerate customer acquisition, partnerships, and revenue growth.

At the same time, we continue to see structural industry challenges. Our biological age prediction remains an emerging category, and many potential customers are still evaluating commercial models. Subscription pricing models require further market education, while kit-based competitors have gained traction through transactional pricing. We believe our long-term differentiation through superior algorithms, clinical utility, and platform integrations will position us well as the market matures.

Product and Technology Development

Throughout 2025, we significantly enhanced the SenoClock® platform, improving both functionality and scalability.

Core Platform Enhancements

Major improvements included:

- Release of SenoClock® Version 2 with enhanced functionality and user experience
- Improvements to the Blood Age report, including Shapley Additive exPlanations (SHAP) based explainability features
- Deployment of upgraded AI parser capabilities to support diverse global lab formats
- Implementation of enhanced application programming interface (API) infrastructure, including rate limiting and improved integration workflows
- Development of improved biometric analysis frameworks and reporting systems

We also introduced improvements to recommendation engines, including personalised dietary and lifestyle recommendations based on allergies, regional dietary patterns, and biomarker data.

These improvements strengthen the platform's value proposition for both enterprise customers and future direct-to-consumer offerings.

New Product Development: Face Age and Biometric Age

A major focus in 2025 was the development of next-generation ageing clocks, including:

- Face Age clock, using AI-based facial image analysis to estimate biological age and identify visible ageing indicators
- Biometric Age clock, integrating physiological and biomarker data into a unified biological age metric

Face Age development progressed significantly during the year, including improvements in image validation, algorithm accuracy, and integration into the SenoClock® platform. We expect Face Age to become an important differentiator and commercial driver when launched.

These products expand our addressable market beyond blood-based diagnostics into imaging-based and multi-modal biological age assessment.

Globalisation and Localisation

To support international expansion, we significantly expanded language and regional capabilities across the platform.

During 2025, we introduced or completed report localisation in multiple languages, including:

- Chinese (Simplified and Traditional)
- Spanish
- Portuguese
- Arabic
- Turkish
- Vietnamese
- Czech
- Filipino

We also localised recommendation datasets for North America, India, and Thailand, enabling culturally and medically appropriate recommendations for global customers.

These efforts substantially increase our ability to onboard international customers and scale globally.

Customer Integration and Platform Adoption

We onboarded, supported, or provided platform access to multiple clinics and healthcare providers during the year, including integrations, demos, and deployment support.

We continued to improve onboarding workflows, including the development of a dedicated onboarding application and improved integration infrastructure. These changes reduce implementation friction and improve scalability.

Customer support and technical infrastructure were strengthened through improved account management, data handling, and platform reliability.

Algorithm and AI Research Advancements

Our research and development team made significant progress in improving the scientific and technical foundation of our biological age models.

Key achievements included:

- Implementation of improved Blood Age algorithms with enhanced explainability and outlier handling
- Comparative testing of multiple AI models
- Exploration of Dunedin Pace of Ageing methodology and integration feasibility
- Development and testing of enhanced biomarker interpretation systems
- Expansion and analysis of large-scale biological age datasets
- Development of advanced PDF parsing systems capable of handling global lab report formats
- Evaluation of models for report analysis, translation, and recommendation generation

We also explored adjacent opportunities, including pet ageing clocks and AI-based medical report interpretation, which may represent future product expansion opportunities.

These efforts strengthen our scientific credibility, improve accuracy, and expand the platform's long-term capabilities.

Strategic Positioning and Outlook

The longevity sector continues to transition from early experimentation toward broader clinical and commercial adoption. While adoption remains uneven and competitive pressures persist, our investments in platform capability, product expansion, and commercial infrastructure have strengthened our long-term positioning.

We enter 2026 with several key advantages:

- Expanded global footprint and commercial pipeline
- Strengthened US market presence
- Improved product platform and customer experience
- New product innovations, including Face Age and Biometric Age
- Enhanced AI and algorithmic capabilities
- Greater scalability through localisation and integrations

We believe these investments position Deep Longevity to accelerate commercial traction, expand customer adoption, and build long-term leadership in the biological age and longevity analytics market.

LOAN CAPITALISATION

On 7 April 2025, the Company and Galloway entered into the Debt Settlement Agreement, pursuant to which the parties conditionally agreed that Galloway shall subscribe for, and the Company shall allot and issue, the Capitalisation Shares at the Capitalisation Price. The Capitalisation Price was equal to the closing price of HK\$0.485 per Share as quoted on the Stock Exchange on 7 April 2025, being the date of the Debt Settlement Agreement and also represented the net price of the Capitalisation Share. The aggregate Capitalisation Price of all Capitalisation Shares payable by Galloway was satisfied by capitalising and setting off against the shareholder's loans and accrued interest, amounting to US\$3,956,484, upon completion on 25 June 2025.

The shareholder's loans were provided by Galloway to the Group for the purpose of financing the Group's general working capital requirements. As at the date of the Debt Settlement Agreement, the settled amount represented the aggregate outstanding shareholder's loans of US\$3,810,000 and the accrued interest of US\$146,484, respectively. The shareholder's loans were unsecured and bore interest at the rates ranging from 8% to 12% per annum.

Upon completion on 25 June 2025, the Capitalisation Shares were allotted and issued to Galloway under the Specific Mandate at the Capitalisation Price. The aggregate nominal value of the Capitalisation Shares issued was US\$63,377.16. There were no remaining net proceeds from the allotment and issue of the Capitalisation Shares available to be utilised by the Company.

USE OF PROCEEDS FROM THE LOAN CAPITALISATION

As the entire aggregate Capitalisation Price payable by Galloway under the Debt Settlement Agreement had been satisfied by capitalising and setting off against the shareholder's loans and the accrued interest, amounting to US\$3,956,484, upon completion on 25 June 2025, there were no remaining net proceeds from the allotment and issue of the Capitalisation Shares available to be utilised by the Company. The use of proceeds is consistent with the intentions previously disclosed in the Company's announcement dated 7 April 2025 and circular dated 16 May 2025. There has been no change or delay in the use of proceeds.

As at 30 June 2025, the net proceeds of Loan Capitalisation had been fully utilised as follows:

	Proposed use of net proceeds as disclosed in the announcement dated 7 April 2025 and the circular dated 16 May 2025		Actual use of net proceeds up to 30 June 2025		Unutilised net proceeds as of 30 June 2025	
	HK\$ million	US\$ million	HK\$ million	US\$ million	HK\$ million	US\$ million
Set off	30.74	3.96	(30.74)	(3.96)	–	–

Outlook for 2026

Looking ahead, we believe the outlook remains positive, with the anticipated approval of Senstend™ in China in the first half of 2026, followed by the commercialisation of Senstend™ in the second half of 2026, where we expect robust demand for our innovative product. This expected growth should lead to increased royalty income for the Group in 2026 and beyond.

In respect of Deep Longevity, we believe that the investment being made in launching our US platform together with our improved product platform and product innovations from our enhanced AI and algorithmic capabilities will help position Deep Longevity to accelerate its commercial traction, expand its customer adoption, and build long-term leadership in the biological age and longevity analytics market.

For the Company, the key priorities in the coming years include expanding the commercial reach of our existing products by exploring strategic partnerships and licensing opportunities that will generate royalty and milestone income and enhance our capabilities and product portfolio.

At the same time, the Board remains mindful of the broader geopolitical tensions, macroeconomic, and industry dynamics, including evolving reimbursement environments, regulatory developments, and competitive pressures within the sector. The Company will continue to pursue growth with a disciplined and strategic approach.

Strategic Plan

The Board and the Company's senior management play an active role in the Company's strategy development and planning process. The CEO regularly interacts with the Board in respect of the strategic plan and direction of the Company, during which an agreed approach for the Company to generate and preserve its long-term value was determined, while agreeing shorter term priorities and objectives. In addition, the risks associated with the current operations and strategy of the Company are currently being tested by way of an internal audit process conducted through an independent service provider, with the aim of identifying ways in which the Company can better identify and manage its risks.

In order to generate or preserve value over the longer term, the Group is committed to:

- the divestment of non-core assets and investments to enable the Company to pursue growth and opportunistic investments in the life sciences sector;
- utilising international and local expertise to tackle difficult markets, deliver results and achieve global recognition; and
- employing the Company's Hong Kong listing through strong liquidity and access to international capital markets, together with maintaining our corporate governance and social responsibility standards in line with the policies set down by the Stock Exchange and best practice.

The Company is committed to creating Shareholder value and returns through accretive acquisitions and returning surplus capital to Shareholders by way of an effective dividend policy and share repurchase programme.

Funding

As at 31 December 2025, the Group had approximately US\$135,000 in cash. On 26 March 2026, Galloway granted a facility which is unsecured and interest bearing to the Company for an amount of up to US\$3,000,000.

Gearing Ratio

Due to the capital deficiency position as at 31 December 2025, the gearing ratio calculated as a percentage of the Group's long-term debts over total equity became a meaningless figure (31 December 2024: meaningless figure).

Contingent Liabilities

The Group had no material contingent liabilities as at 31 December 2025 (31 December 2024: nil).

Significant Investments

As at 31 December 2025, the Group did not have any significant investment in equity interest in any other companies and did not own any properties (31 December 2024: nil).

Material Acquisitions and Disposals of Subsidiaries

The Group did not have any material acquisition or disposal of subsidiary during the year ended 31 December 2025 (year ended 31 December 2024: nil).

Material Changes for the Year Ended 31 December 2025

Save as disclosed in this announcement, there were no significant changes in the Group's financial position and from the information disclosed under Management's Discussion and Analysis of the Group's Performance in the announcement for the year ended 31 December 2025.

Charge on Assets

As at 31 December 2025, a bank deposit amounting to US\$32,000 is a deposit held by the bank as security for the corporate credit cards provided to a subsidiary of the Company (31 December 2024: US\$32,000).

Management of Risk

The most significant risks affecting the profitability and viability in respect of the Group is the Group's interest in Plethora. Key risks relating to the Group's interests include:

Foreign Exchange Risk

The Group operates using US dollars. As such, the Group is exposed to foreign currency fluctuations arising from operations of its subsidiaries and associate. This exposure relates mainly to the translation between US dollars and non-US dollar currencies. Currency fluctuations may affect the revenues which the Group realises from its subsidiaries and associate and, in particular, its interest in Plethora. This exposes the Group to increased volatility in earnings as reported in US dollars due to fluctuations in foreign exchange rates. While foreign currencies are generally convertible into US dollars, there is no guarantee that they will continue to be so convertible or that fluctuations in the value of such currencies will not have an adverse effect on the Group.

Interest Rate Risk

Other than the bank borrowings and shareholder's loans with fixed interest rates, the Group does not have any other operating lines of credit and bank facilities. Therefore, the Group was not exposed to interest rate risk in the financial year under review.

Risks Inherent to Plethora (the Company's most significant investment)

- The timing and quantum of receipt of upfront, milestone and royalty income from strategic commercial marketing partners, which in itself is dependent on the successful partnering and the commercial launch of Fortacin™/Senstend™;
- The management of Plethora's cost base and maintaining adequate working capital and ensuring sufficient funds are made available to complete the ongoing clinical work and regulatory approval processes in the US and bringing Fortacin™/Senstend™ to market;
- The retention of key employees to complete the commercialisation process;
- Delays and other unforeseen disruptions to the manufacturing and regulatory approval projects which could have an adverse impact on the commercial launch of Fortacin™/Senstend™ and future revenues; and
- The exposure to competition from new generic entrants into the market.

Financial Instruments

The Group will operate both equity market and currency hedges from time to time. Investment is carefully controlled, in accordance with parameters set by the Board, in short-term situations where physical assets may be inappropriate. There is strict segregation between the investment management and settlement functions.

In term of the total operations of the Group, activities of this nature are of limited materiality.

Foreign Currency

The Group had not taken out any currency hedge as the management is not aware of any material foreign currency risk against its investments in financial assets. Currently, the Group has no material financial liabilities denominated in foreign currencies other than US dollars.

Segmental Information

For details of the segment information, please refer to note 4 to this announcement.

Employees

The Group, including subsidiaries but excluding associate, employed 16 employees and 1 consultant as at 31 December 2025 (31 December 2024: 17 employees and 1 consultant). The remuneration policy is to reward key employees by a combination of salaries, profit related discretionary bonuses and share options, where appropriate. For employees below Board level, remuneration is determined by the Director(s) responsible for the division whilst, for Non-Executive Directors (including Independent Non-Executive Directors), remuneration is recommended by the Remuneration Committee and approved by the Board. For individual Executive Director and senior management, the Remuneration Committee determines, with delegated responsibility, their remuneration packages. In all cases, profit related discretionary bonuses and grants of share options will be agreed by the Remuneration Committee.

FINAL DIVIDEND

The Directors have resolved not to declare a final dividend in respect of the year ended 31 December 2025 (year ended 31 December 2024: nil).

THE CORPORATE GOVERNANCE CODE

The Company is committed to achieving and maintaining high standards of corporate governance. During the year ended 31 December 2025, the Company has complied with the Code Provisions set out in the CG Code. The Board is responsible for performing the corporate governance functions as set out under Code Provision A.2.1 of the CG Code.

Reference is made to the announcement of the Company in relation to the change of Auditor dated 21 June 2023. The Board had conducted an external audit tender process in accordance with good corporate governance practice as BDO Limited (“**BDO**”), the resigning external Auditor of the Company, has provided auditing services to the Company for 12 financial years. As a result of this process, the Company announced that BDO had resigned as the Auditor with effect from 21 June 2023 and RSM Hong Kong (“**RSM**”) had been appointed as the Auditor with effect from 21 June 2023. BDO had confirmed in its resignation letter to the Company and the Audit Committee that there were no matters in respect of its resignation that needed to be brought to the attention of the holders of securities of the Company.

The Board, with the recommendation of the Audit Committee, had resolved to appoint RSM with effect from 21 June 2023 as the new Auditor to fill the casual vacancy following the resignation of BDO, and to hold office until the conclusion of the next annual general meeting of the Company subject to appointment by the Shareholders in accordance with the articles of association of the Company by way of ordinary resolution. The ordinary resolution to re-appoint RSM as the Auditor had been passed by the Shareholders at the annual general meeting of the Company held on 30 May 2024.

Reference is also made to the announcement of the Company in relation to the change of Auditor dated 16 July 2024. The Company announced that RSM had resigned as the external Auditor with effect from 16 July 2024 as the Board and RSM could not reach a consensus on the audit fee for the financial year ended 31 December 2024. The Audit Committee had reviewed the audit fee proposal provided by RSM and considered that the proposed audit fee might not be appropriate considering the current operation scale of the Group and the prevailing market rates from other professional accounting firms of a similar scale. RSM had confirmed in its resignation letter to the Company and the Audit Committee that there were no matters in respect of its resignation that needed to be brought to the attention of the holders of securities of the Company.

The Board, with the recommendation of the Audit Committee, had resolved to appoint Baker Tilly Hong Kong Limited (“**Baker Tilly**”) with effect from 16 July 2024 as the new Auditor to fill the casual vacancy following the resignation of RSM, and to hold office until the next annual general meeting of the Company. The ordinary resolution to re-appoint Baker Tilly as the Auditor had been passed by the Shareholders at the annual general meeting of the Company held on 19 June 2025.

REVIEW BY THE AUDIT COMMITTEE AND AUDITOR

The final results and the audited financial statements of the Group for the year ended 31 December 2025 have been reviewed by the Audit Committee in conjunction with the Company’s independent auditor, Baker Tilly.

SCOPE OF WORK OF AUDITOR

The figures in respect of the Group's consolidated statement of profit or loss and other comprehensive income, consolidated statement of financial position and the related notes thereto for the year ended 31 December 2025 as set out in this final results announcement have been agreed by the Group's independent auditor, Baker Tilly, to the amounts set out in the Group's audited consolidated financial statements for the year ended 31 December 2025. The work performed by Baker Tilly in this respect did not constitute an assurance engagement and consequently no opinion or assurance has been expressed by Baker Tilly on this final results announcement.

PURCHASE, SALE AND REDEMPTION OF LISTED SECURITIES

For the year ended 31 December 2025, neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the Company's listed securities (including Treasury Shares, if any).

For the year ended 31 December 2025, the Company did not hold any Treasury Shares whether in the Central Clearing and Settlement System, or otherwise.

EXTRACT OF INDEPENDENT AUDITOR'S REPORT

The following is an extract of the independent auditor's report on the Group's consolidated financial statements for the year ended 31 December 2025:

"Opinion

In our opinion, the consolidated financial statements give a true and fair view of the consolidated financial position of the Group as at 31 December 2025, and of its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with HKFRS Accounting Standards as issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA") and have been properly prepared in compliance with the disclosure requirements of the Hong Kong Companies Ordinance.

Material Uncertainty Related to Going Concern

We draw attention to Note 3 to the consolidated financial statements, which indicates that the Group incurred a loss of approximately US\$4,710,000 during the year ended 31 December 2025 and, as of that date, the Group had net current liabilities and net liabilities of approximately US\$6,645,000 and US\$6,641,000, respectively. As stated in Note 3, these conditions indicate that a material uncertainty exists that may cast significant doubt on the Group's ability to continue as a going concern. Our opinion is not modified in respect of this matter."

PUBLICATION ON WEBSITES

This announcement is published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.regentpac.com).

DESPATCH OF ANNUAL REPORT

The 2025 Annual Report containing full details of the Company's audited consolidated results for the year ended 31 December 2025 will be available on the websites of the Stock Exchange and the Company and be despatched to the Shareholders by the end of April 2026.

By Order of the Board
Regent Pacific Group Limited
James Mellon
Chairman

Hong Kong, 26 March 2026

As at the date of this announcement, the Board comprises six Directors:

Executive Director:

Jamie Gibson (*Chief Executive Officer*)

Non-Executive Directors:

James Mellon (*Chairman*)

Jayne Sutcliffe

Independent Non-Executive Directors:

Mark Searle

Adrian Chan

Ihsan Al Chalabi

DEFINITIONS

In this final results announcement, the following expressions shall have the following meanings unless the context indicates otherwise:

2025 Annual Report	the Company's annual report for the year ended 31 December 2025
2025 AGM	the last annual general meeting of the Company held on 19 June 2025
AI	artificial intelligence
Auditor	the auditor of the Group
Audit Committee	audit committee of the Company
Board or Board of Directors	Board of Directors of the Company
Capitalisation Price	HK\$0.485 per Capitalisation Share
Capitalisation Share(s)	63,377,163 Shares allotted and issued to Galloway by the Company at the Capitalisation Price pursuant to the Debt Settlement Agreement, completed on 25 June 2025
CEO	Chief Executive Officer of the Company
CG Code	Corporate Governance Code as set out in Appendix C1 of the Listing Rules
Company or Regent Pacific	Regent Pacific Group Limited, a company incorporated in the Cayman Islands with limited liabilities, the shares of which are listed on the Main Board of the Stock Exchange and are also traded on the Open Market (Freiverkehr) of the Frankfurt Stock Exchange

Debt Settlement Agreement	the conditional agreement dated 7 April 2025 entered into between Galloway and the Company in relation to the Loan Capitalisation
Deep Longevity	Deep Longevity, Inc, a wholly-owned subsidiary of the Company, and its subsidiary
Director(s)	director(s) of the Company
FAFVPL	financial assets at fair value through profit or loss
FDA	The Food and Drug Administration of the US
G&A	general and administrative
Galloway	Galloway Limited, a private limited liability company which is indirectly wholly-owned by James Mellon, a substantial Shareholder who is also a Non-Executive Director and Chairman of the Board
GBP	Great British pounds, the lawful currency in the UK
Group	the Company and its subsidiaries
HK\$	Hong Kong dollars, the lawful currency in Hong Kong
HKAS(s)	Hong Kong Accounting Standard(s)
HKICPA	the Hong Kong Institute of Certified Public Accountants
Hong Kong	The Hong Kong Special Administrative Region of the PRC
Hong Kong Companies Ordinance	Companies Ordinance (Chapter 622 of the Laws of Hong Kong)
IP	intellectual property

Listing Rules	Rules Governing the Listing of Securities on the Stock Exchange
Loan Capitalisation	conversion of the shareholder's loan of US\$3,810,000 and the accrued interest of US\$146,484 into the share capital of the Company by applying such the shareholder's loans and the accrued interest in payment of the subscription amount credited as fully paid to Galloway under the Debt Settlement Agreement
NDA	New Drug Application
NMPA	the National Medical Products Administration
Plethora	Plethora Solutions Holdings plc, a wholly-owned subsidiary of the Company
PRC or China	The People's Republic of China
R&D	research and development
Recordati	Recordati S.p.A
Remuneration Committee	remuneration committee of the Company
Share(s)	ordinary share(s), with voting rights, of US\$0.001 each in the capital of the Company
Shareholder(s)	holder(s) of the Share(s)
Stock Exchange	The Stock Exchange of Hong Kong Limited
Treasury Share(s)	has the meaning ascribed to it in the Listing Rules
UK	the United Kingdom
US	the United States

US\$

US dollars, the lawful currency in the US

Wanbang
Biopharmaceutical

江蘇萬邦生化醫藥集團有限責任公司 (Jiangsu Wanbang Biopharmaceutical Group Co., Ltd.), a wholly-controlled company of 上海復星醫藥(集團)股份有限公司 (Shanghai Fosun Pharmaceutical (Group) Co., Ltd.)